Microbiome-Drug Interactions: A Critical Review of Pharmacokinetic and Pharmacodynamic Modulation
Keywords:
Pharmacomicrobiomics, Regulatory oversight, Precision medicine, Bioaccumulation.Abstract
The human microbiome functions as a powerful metabolic organ that affects drug pharmacokinetics and pharmacodynamics (PK/PD). While pharmaceuticals simultaneously alter microbial communities—a process known as pharmacoecology and toxicomicrobiomics—this reciprocal relationship, known as Pharmacomicrobiomics is the study of how microbial variety impacts the toxicity and effectiveness of medications. Microbes have the power to activate medications, bioaccumulate, inactivate prodrugs, and chemically alter pharmaceuticals—all of which have a significant impact on how various patients react to treatment. The microbial genes, enzymes, and pathways involved in medication biotransformation, which have been mapped by improvements in multi-omics profiling, inspire innovative therapies such as probiotics, enzyme inhibitors, dietary modifications, and fecal microbiota transplantation to optimize therapy. These tactics seek to decrease adverse medication reactions and improve treatment precision. However, there are ethical and regulatory issues in creating treatments based on the microbiota. The classification, manufacturing standards, safety, informed consent, privacy, equity, and long-term monitoring of live biotherapeutics, prebiotics, probiotics, and transplants must all be covered in their respective frameworks. Personal identification, biobanking, and the social repercussions of microbiome modification are further ethical issues. In conclusion, incorporating microbiome science into pharmacology has the potential to revolutionize precision medicine; nevertheless, strict ethical and regulatory control is necessary for its safe, equitable, and moral clinical application.
Downloads
References
Belkaid, Y., Hand, T.W. (2014), "Role of the microbiota in immunity and inflammation", Cell, 157(1), 121-131.
Lloyd-Price, J., et al. (2016), "Strains, functions and dynamics in the human microbiome", Nature, 533(7602), 59-65.
Shreiner, A.B., et al. (2015), "The gut microbiome in health and in disease", Curr. Opin. Gastroenterol., 31(1), 69-75.
Turnbaugh, P.J., et al. (2007), "The human microbiome project", Nature, 449(7164), 804-810.
Bengmark, S. (2017), "The gut microbiota and its implications for pharmacology", Eur. J. Pharmacol., 794, 10-17.
Brown, A.D., et al. (2019), "Microbial modulation of drug absorption: A review", Drug Metab. Rev., 51(4), 443-457.
Chow, J.S., et al. (2021), "Impact of the gut microbiota on drug metabolism and toxicity", J. Clin. Pharmacol., 61(3), 360-370.
Forsyth, C.B., et al. (2020), "Gut microbiota modulation of drug absorption: Implications for drug development", J. Pharmacol. Exp. Ther., 373(3), 444-453.
Jeffery, I.B., et al. (2016), "Gut microbiome influences drug metabolism", Nat. Rev. Gastroenterol. Hepatol., 13(7), 382-396.
Koppel, N., et al. (2017), "The influence of the human microbiome on the pharmacokinetics of drugs", Trends Pharmacol. Sci., 38(6), 393-402.
Li, J., et al. (2020), "Influence of the gut microbiota on drug metabolism", Nat. Rev. Drug Discov., 19(8), 439-453.
Wikoff, W.R., et al. (2017), "Gut microbiota and pharmacology: Microbial modulation of drug transporters", Nat. Rev. Gastroenterol. Hepatol., 14(7), 385-395.
Zimmermann, M., et al. (2019), "Microbial metabolism of drugs in the human gut microbiota: A review of the enzymatic mechanisms", Microorganisms, 7(7), 253-267.
ElRakaiby, M., et al. (2014), "Pharmacomicrobiomics: The impact of human microbiome variations on systems pharmacology and personalized therapeutics", OMICS, 18(7), 402-414.
Gopalakrishnan, V., et al. (2018), "Gut microbiome modulates response to anti–PD-1 immunotherapy in melanoma patients", Science, 359(6371), 97-103.
Haiser, H.J., et al. (2013), "Predicting and manipulating cardiac drug inactivation by the human gut bacterium Eggerthella lenta", Science, 341(6143), 295-298.
Koh, A., et al. (2016), "From dietary fiber to host physiology: Short-chain fatty acids as key bacterial metabolites", Cell, 165(6), 1332-1345.
Spanogiannopoulos, P., et al. (2016), "The microbial pharmacists within us: A metagenomic view of xenobiotic metabolism", Nat. Rev. Microbiol., 14(5), 273-287.
Zmora, N., et al. (2019), "You are what you eat: Diet, health and the gut microbiota", Nat. Rev. Gastroenterol. Hepatol., 16(1), 35-56.
Bengmark, S. (2017), "The gut microbiota and its implications for pharmacology", Eur. J. Pharmacol., 794, 10-17.
Brown, A.D., et al. (2019), "Microbial modulation of drug absorption: A review", Drug Metab. Rev., 51(4), 443-457.
Chow, J.S., et al. (2021), "Impact of the gut microbiota on drug metabolism and toxicity", J. Clin. Pharmacol., 61(3), 360-370.
Foster, J.A., et al. (2018), "The microbiome and pharmacology: Microbial modulation of drug action", Pharmacol. Rev., 70(2), 356-365.
Jeffery, I.B., et al. (2016), "Gut microbiome influences drug metabolism", Nat. Rev. Gastroenterol. Hepatol., 13(7), 382-396.
Koppel, N., et al. (2017), "The influence of the human microbiome on the pharmacokinetics of drugs", Trends Pharmacol. Sci., 38(6), 393-402.
Zimmermann, M., et al. (2019), "Microbial metabolism of drugs in the human gut microbiota: A review of the enzymatic mechanisms", Microorganisms, 7(7), 253-267.
Fournier, P.E., et al. (2013), "Antibiotic resistance in the microbiome", Clin. Infect. Dis., 57(10), 1374-1381.
Gopalakrishnan, V., et al. (2018), "The influence of the gut microbiome on the pharmacokinetics of cancer therapeutics", Nat. Rev. Cancer, 18(5), 283-295.
Gonzalez, A., et al. (2016), "The gut microbiome and the psychotropic effects of antidepressants", Nat. Rev. Psychiatry, 13(8), 489-500.
Jernberg, C., et al. (2010), "Long-term impact of antibiotic exposure on the human intestinal microbiota", Microbiology, 156(11), 3216-3223.
Lugli, G.A., et al. (2017), "Impact of proton pump inhibitors on the human gut microbiome: A cross-sectional study", BMC Microbiol., 17(1), 131.
Mao, R., et al. (2020), "Proton pump inhibitors and risk of Clostridium difficile infection", Gastroenterology, 158(3), 692-698.
Wu, H., et al. (2017), "Metformin alters gut microbiome of individuals with treatment-naive type 2 diabetes mellitus", Nature, 535(7612), 406-411.
Zhao, L., et al. (2017), "The gut microbiome and metabolic diseases", Lancet, 387(10024), 297-307.
Zimmermann, M., et al. (2019), "Antibiotic use and the gut microbiota: A review", Front. Microbiol., 10, 1600.
Zhang, H., et al. (2015), "Alterations of the gut microbiome in individuals with major depressive disorder", Front. Psychiatry, 6, 19.
Bengmark, S. (2017), "The gut microbiota and its implications for pharmacology", Eur. J. Pharmacol., 794, 10-17.
Brown, A.D., et al. (2019), "Microbial modulation of drug absorption: A review", Drug Metab. Rev., 51(4), 443-457.
Chow, J.S., et al. (2021), "Impact of the gut microbiota on drug metabolism and toxicity", J. Clin. Pharmacol., 61(3), 360-370.
Fournier, P.E., et al. (2013), "Antibiotic resistance in the microbiome", Clin. Infect. Dis., 57(10), 1374-1381.
Foster, J.A., et al. (2018), "The microbiome and pharmacology: Microbial modulation of drug action", Pharmacol. Rev., 70(2), 356-365.
Gopalakrishnan, V., et al. (2018), "The influence of the gut microbiome on the pharmacokinetics of cancer therapeutics", Nat. Rev. Cancer, 18(5), 283-295.
Jeffery, I.B., et al. (2016), "Gut microbiome influences drug metabolism", Nat. Rev. Gastroenterol. Hepatol., 13(7), 382-396.
Jernberg, C., et al. (2010), "Long-term impact of antibiotic exposure on the human intestinal microbiota", Microbiology, 156(11), 3216-3223.
Koppel, N., et al. (2017), "The influence of the human microbiome on the pharmacokinetics of drugs", Trends Pharmacol. Sci., 38(6), 393-402.
Lugli, G.A., et al. (2017), "Impact of proton pump inhibitors on the human gut microbiome: A cross-sectional study", BMC Microbiol., 17(1), 131.
Wikoff, W.R., et al. (2017), "Gut microbiota and pharmacology: Microbial modulation of drug transporters", Nat. Rev. Gastroenterol. Hepatol., 14(7), 385-395.
Zimmermann, M., et al. (2019), "Microbial metabolism of drugs in the human gut microbiota: A review of the enzymatic mechanisms", Microorganisms, 7(7), 253-267.
Zhang, H., et al. (2015), "Alterations of the gut microbiome in individuals with major depressive disorder", Front. Psychiatry, 6, 19.
Bäckhed, F., et al. (2012), "The gut microbiota as an environmental factor that regulates fat storage", Proc. Natl. Acad. Sci., 103(32), 12500-12505.
Brown, A.D., et al. (2019), "Microbial modulation of drug absorption: A review", Drug Metab. Rev., 51(4), 443-457.
Chow, J.S., et al. (2021), "Impact of the gut microbiota on drug metabolism and toxicity", J. Clin. Pharmacol., 61(3), 360-370.
Fujimoto, T., et al. (2016), "The role of microbiota in the toxicity of drugs and their metabolites", Toxicol. Rep., 3, 200-207.
Gopalakrishnan, V., et al. (2018), "The influence of the gut microbiome on the pharmacokinetics of cancer therapeutics", Nat. Rev. Cancer, 18(5), 283-295.
Iida, N., et al. (2013), "Commensal bacteria control cancer therapy responses", Science, 342(6161), 971-976.
Jeffery, I.B., et al. (2016), "Gut microbiome influences drug metabolism", Nat. Rev. Gastroenterol. Hepatol., 13(7), 382-396.
Jernberg, C., et al. (2010), "Long-term impact of antibiotic exposure on the human intestinal microbiota", Microbiology, 156(11), 3216-3223.
Mao, R., et al. (2020), "Proton pump inhibitors and risk of Clostridium difficile infection", Gastroenterology, 158(3), 692-698.
Perry, R.J., et al. (2016), "Opioid-induced gastrointestinal dysfunction: The role of the microbiome", Clin. Pharmacol. Ther., 99(6), 632-639.
Zhao, L., et al. (2017), "The gut microbiome and metabolic diseases", Lancet, 387(10024), 297-307.
Zhang, H., et al. (2015), "Alterations of the gut microbiome in individuals with major depressive disorder", Front. Psychiatry, 6, 19.
Canfora, E.E., et al. (2015), "Short-chain fatty acids in the control of body weight and insulin sensitivity", Nat. Rev. Endocrinol., 11(10), 577-591.
David, L.A., et al. (2014), "Diet rapidly and reproducibly alters the human gut microbiome", Nature, 505(7484), 559-563.
De Filippis, F., et al. (2016), "High-level adherence to a Mediterranean diet is associated with higher microbial diversity and a more favorable gut microbiota", Gut, 65(11), 1812-1818.
Gopalakrishnan, V., et al. (2018), "The influence of the gut microbiome on the pharmacokinetics of cancer therapeutics", Nat. Rev. Cancer, 18(5), 283-295.
Gionchetti, P., et al. (2014), "Probiotics in inflammatory bowel diseases", Gut, 63(12), 1890-1899.
Jernberg, C., et al. (2010), "Long-term impact of antibiotic exposure on the human intestinal microbiota", Microbiology, 156(11), 3216-3223.
Khan, S.M., et al. (2020), "Probiotics for gut health and the modulation of gut microbiome: A systematic review", World J. Gastroenterol., 26(30), 4565-4574.
Mayer, E.A., et al. (2015), "The gut-brain axis and the microbiome: Implications for mood disorders", Psychiatr. Clin. North Am., 38(3), 453-464.
McFarland, L.V. (2015), "Systematic review and meta-analysis of probiotics for the treatment of Clostridium difficile infection", J. Hosp. Infect., 85(1), 63-72.
Pistollato, F., et al. (2020), "The role of the gut microbiota in neurodegenerative diseases", Neuroscience, 429, 143-157.
Slavin, J.L. (2013), "Dietary fiber and prebiotics and the gastrointestinal microbiota", J. Clin. Gastroenterol., 47(3), 117-119.
van Nood, E., et al. (2013), "Duodenal infusion of donor feces for recurrent Clostridium difficile", N. Engl. J. Med., 368(5), 407-415.
Zhang, X., et al. (2020), "Pharmacomicrobiomics: The role of the microbiome in drug response", Pharmacol. Res., 158, 104870.
Berg, J.M. (2019), "Ethics in microbiome research: A focus on privacy and ownership of data", Nat. Biotechnol., 37(8), 929-935.
Berkman, B., Zucker, L. (2021), "Informed consent and autonomy in microbiome research", J. Med. Ethics, 47(1), 1-8.
Dodd, C.E., et al. (2017), "Microbiome-based therapies: Long-term effects and ethical considerations", Nat. Rev. Microbiol., 15(3), 181-188.
Swanson, K.S., et al. (2020), "The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of synbiotics", Nat. Rev. Gastroenterol. Hepatol., 17(11), 687-701.
Dube, E.M., et al. (2021), "Addressing health disparities in microbiome-based therapies", J. Health Equity, 3(4), 123-130.
European Commission (2006), "Commission directive 2006/141/EC on infant formulae and follow-on formulae", Off. J. Eur. Union.
Galli, C., et al. (2020), "Microbiome privacy: Ethical issues in genomic and microbiome data", Genomics Soc. Policy, 17(1), 13-20.
Gopalakrishnan, V., et al. (2018), "The influence of the gut microbiome on the pharmacokinetics of cancer therapeutics", Nat. Rev. Cancer, 18(5), 283-295.
Hoffman, J.R., et al. (2020), "Access to microbiome-based therapies in low-resource settings", Glob. Health Action, 13(1), 1853506.
Hollis, A., et al. (2019), "Ethics of animal experimentation in microbiome research", Sci. Eng. Ethics, 25(3), 759-772.
Lange, K.M., et al. (2020), "Ethical considerations in microbiome-modulating human clinical trials", Ethics Med., 21(2), 97-104.
Lee, C.H., et al. (2016), "Fecal microbiota transplantation: Ethical and safety considerations", J. Clin. Gastroenterol., 50(6), 465-468.
Marchesi, J.R., et al. (2016), "Pharmacomicrobiomics: The role of the microbiome in drug response", Pharmacol. Res., 105, 72-80.
Patel, M.M., et al. (2021), "Microbiome manipulation and its unintended environmental consequences", Ecol. Appl., 31(5), e02387.
U.S. Food and Drug Administration (2013), "Fecal microbiota transplantation for the treatment of recurrent Clostridium difficile infection", FDA News, 1(3), 1-5.
Weber, M.H., et al. (2017), "Regulatory challenges in the clinical use of probiotics and microbiome-modulating products", Front. Microbiol., 8, 1792.
Zhu, C., et al. (2019), "Safety and donor screening in fecal microbiota transplantation", Gastroenterol. Res. Pract., 2019, 1-9.
Published
How to Cite
Issue
Section
Copyright (c) 2025 Tropical Journal of Pharmaceutical and Life Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright Policy & Licensing terms | Tropical Journal of Pharmaceutical and Life Sciences
